切换导航
About Us
Our Story
Our Mission
History
Global Footprint
Leadership
Board of Directors
Science & Technology
Pipeline
Collaborations
CDMO Services
About CDMO
Strength
Services Offered
Learn More
Investors & Media
Join Us
EN
中文
Our RNA Encodes
Innovation
/science.html
Transforming Somatic Cells into a Drug Factory
View More
Latest news
News Update
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
View More
2023.01.09
News Update
Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine
View More
2022.11.19
News Update
First Patient Dosed in Phase 1 FIH Study of JCXH-211, the First-in-Class Self-Replicating RNA encoding human IL-12, in Patients with Malignant Solid Tumors
View More
2022.11.07
Immorna Receives IND Clearance to Conduct FIH Study of JCXH-211, the First-in-Class Self-replicating mRNA
View More
2022.03.28
View All
Diverse pipeline utilizing multiple mRNA platforms, including conventional, self-replicating and circular mRNA.
View More